On October 1, 2020, the Maine Department of Corrections (MDOC) announced that it would provide expanded access to medication treatment for more than 500 inmates in its custody with chronic Hepatitis C virus (HCV). This medication treatment is in the form of direct-acting antivirals. The MDOC expanded access as part of its settlement in the Loisel v. Clinton class-action lawsuit filed in 2019. The plaintiffs alleged that MDOC’s failure to provide HCV treatment until the disease had progressed to the point of causing permanent liver damage violated the Americans with Disabilities Act. As of October . . .